Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder
Supernus Pharmaceuticals (Nasdaq: SUPN) has announced a webcast and conference call scheduled for Thursday, October 17, 2024, at 4:30 p.m. ET. The purpose of this event is to review data from the open-label Phase 2a study of SPN-820, a treatment for major depressive disorder. The company, which focuses on developing and commercializing products for central nervous system (CNS) diseases, will provide a live webcast with presentation slides accessible via a specific link or through the Events & Presentations section of their Investor Relations website.
Following management's prepared remarks and discussion of the interim trial results, there will be a Q&A session. Participants can pre-register for the call and will receive a personalized dial-in number. A replay of the call will be available on the company's website, with the webcast remaining accessible for 60 days after the live call.
Supernus Pharmaceuticals (Nasdaq: SUPN) ha annunciato una webcast e una conference call programmata per giovedì 17 ottobre 2024, alle 16:30 ET. Lo scopo di questo evento è rivedere i dati dello studio open-label di Fase 2a di SPN-820, un trattamento per il disturbo depressivo maggiore. L'azienda, che si concentra sullo sviluppo e la commercializzazione di prodotti per le malattie del sistema nervoso centrale (SNC), offrirà una webcast in diretta con le diapositive di presentazione accessibili tramite un link specifico o attraverso la sezione Eventi & Presentazioni del loro sito web per le relazioni con gli investitori.
Successivamente alle osservazioni preparate dalla dirigenza e alla discussione dei risultati provvisori dello studio, ci sarà una sessione di domande e risposte. I partecipanti possono registrarsi in anticipo per la chiamata e riceveranno un numero di accesso personalizzato. Una registrazione della chiamata sarà disponibile sul sito web dell'azienda, con la webcast che rimarrà accessibile per 60 giorni dopo la chiamata dal vivo.
Supernus Pharmaceuticals (Nasdaq: SUPN) ha anunciado una retransmisión en vivo y una conferencia telefónica programada para el jueves 17 de octubre de 2024, a las 4:30 p.m. ET. El propósito de este evento es revisar los datos del estudio abierto de Fase 2a de SPN-820, un tratamiento para el trastorno depresivo mayor. La compañía, que se centra en desarrollar y comercializar productos para enfermedades del sistema nervioso central (SNC), ofrecerá una retransmisión en vivo con diapositivas de presentación accesibles a través de un enlace específico o en la sección de Eventos y Presentaciones de su sitio web de Relaciones con Inversores.
Después de las observaciones preparadas por la dirección y la discusión de los resultados interinos del ensayo, habrá una sesión de preguntas y respuestas. Los participantes pueden preinscribirse para la llamada y recibirán un número de acceso personalizado. Se dispondrá de una grabación de la llamada en el sitio web de la empresa, y la retransmisión permanecerá accesible durante 60 días después de la llamada en vivo.
슈퍼너스 제약회사(Supernus Pharmaceuticals, Nasdaq: SUPN)가 2024년 10월 17일 목요일 오후 4시 30분 ET에 웹캐스트 및 컨퍼런스 콜을 개최한다고 발표했습니다. 이 행사의 목적은 SPN-820의 오픈 라벨 2a 단계 연구 데이터 검토입니다. 주요 우울 장애에 대한 치료법인 SPN-820은 중추 신경계(CNS) 질환을 위한 제품 개발 및 상용화에 집중하는 회사입니다. 회사는 특정 링크를 통해 또는 투자자 관계 웹사이트의 이벤트 및 발표 섹션을 통해 접근할 수 있는 발표 슬라이드와 함께 라이브 웹캐스트를 제공할 것입니다.
경영진의 준비된 발언과 중간 시험 결과에 대한 논의 후, 질문 및 답변 세션이 있을 예정입니다. 참가자는 콜에 사전 등록할 수 있으며 개인화된 다이얼 인 번호를 받게 됩니다. 콜 녹화는 회사 웹사이트에서 이용 가능하며, 라이브 콜 후 60일 동안 웹캐스트에 접근할 수 있습니다.
Supernus Pharmaceuticals (Nasdaq: SUPN) a annoncé une diffusion web et une conférence téléphonique prévue pour le jeudi 17 octobre 2024, à 16h30 ET. L'objectif de cet événement est de réviser les données de l'étude à étiquetage ouvert de phase 2a de SPN-820, un traitement pour le trouble dépressif majeur. L'entreprise, qui se concentre sur le développement et la commercialisation de produits pour les maladies du système nerveux central (SNC), proposera une diffusion en direct avec des diapositives de présentation accessibles via un lien spécifique ou à travers la section Événements et Présentations de son site Internet pour les relations avec les investisseurs.
Après les remarques préparées de la direction et la discussion des résultats préliminaires de l'essai, il y aura une session de questions-réponses. Les participants peuvent s'inscrire à l'avance pour l'appel et recevront un numéro d'appel personnalisé. Un enregistrement de l'appel sera disponible sur le site Internet de l'entreprise, la diffusion restant accessible pendant 60 jours après l'appel en direct.
Supernus Pharmaceuticals (Nasdaq: SUPN) hat eine Webcast und Telefonkonferenz für Donnerstag, den 17. Oktober 2024, um 16:30 Uhr ET angekündigt. Ziel dieser Veranstaltung ist es, die Daten aus der offenen Phase-2a-Studie von SPN-820 zu überprüfen, einer Behandlung für Major Depression. Das Unternehmen, das sich auf die Entwicklung und Vermarktung von Produkten für Erkrankungen des zentralen Nervensystems (ZNS) konzentriert, wird einen Live-Webcast mit Präsentationsfolien anbieten, die über einen bestimmten Link oder über den Bereich Veranstaltungen & Präsentationen auf der Website der Investor Relations zugänglich sind.
Nach den vorbereiteten Bemerkungen des Managements und der Diskussion der vorläufigen Studienergebnisse wird es eine Q&A-Session geben. Teilnehmer können sich im Voraus für den Anruf registrieren und erhalten eine personalisierte Einwahlnummer. Eine Aufzeichnung des Anrufs wird auf der Website des Unternehmens verfügbar sein, wobei der Webcast 60 Tage lang nach dem Live-Anruf zugänglich bleibt.
- Supernus Pharmaceuticals is progressing with Phase 2a study of SPN-820 for major depressive disorder
- The company is demonstrating transparency by hosting a webcast to review study data with investors
- None.
ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company will hold a webcast and conference call on Thursday, October 17, 2024, at 4:30 p.m. ET to review data from the open-label Phase 2a study of SPN-820 for the treatment of major depressive disorder.
A live webcast with presentation slides will be available via this webcast link or in the Events & Presentations section of the Company’s Investor Relations website at www.supernus.com/investors. Following management’s prepared remarks and discussion of the interim trial results, the call will open for questions.
Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.
Following the live call, a replay will be available on the Company's Investor Relations website at www.supernus.com/investors. The webcast will be available on the Company’s website for 60 days following the live call.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease (PD), cervical dystonia, chronic sialorrhea, and dyskinesia in PD patients receiving levodopa-based therapy. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.
For more information, please visit www.supernus.com.
Forward Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company’s ability to sustain and increase its profitability; the Company’s ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company’s corporate strategy; the Company’s future financial performance and projected expenditures; the Company’s ability to increase the number of prescriptions written for each of its products and the products of its subsidiaries; the Company’s ability to increase its net revenue from its products and the products of its subsidiaries; the Company’s ability to commercialize its products and the products of its subsidiaries; the Company’s ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company’s product research and development activities, including the timing and progress of the Company’s clinical trials, and projected expenditures; the Company’s ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company’s product candidates; the Company’s ability to protect its intellectual property and the intellectual property of its subsidiaries and operate its business without infringing upon the intellectual property rights of others; the Company’s expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company’s product candidates; the accuracy of the Company’s estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company’s ability to increase its manufacturing capabilities for its products and product candidates; the Company’s projected markets and growth in markets; the Company’s product formulations and patient needs and potential funding sources; the Company’s staffing needs; and other risk factors set forth from time to time in the Company’s filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.
CONTACTS:
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591
or
INVESTOR CONTACT:
Peter Vozzo
ICR Westwicke
(443) 213-0505
peter.vozzo@westwicke.com
FAQ
When is Supernus Pharmaceuticals (SUPN) hosting the webcast for SPN-820 Phase 2a study results?
What is the purpose of Supernus Pharmaceuticals' (SUPN) upcoming webcast?
How can investors access Supernus Pharmaceuticals' (SUPN) webcast on SPN-820 study results?
What type of study is Supernus Pharmaceuticals (SUPN) conducting for SPN-820?
